SEATTLE--(BUSINESS WIRE)--Harmonization — establishing standard processes and operating procedures across a global laboratory network — can be a challenge, but is essential to ensuring testing accuracy for clinical trials. When LabConnect hosted its annual Global Lab Affiliates Meeting this summer bringing together affiliate laboratories from around the world, harmonization was at the top of the agenda.
“Today’s central lab must ensure lab harmonization to drive quality data, cost savings and global integration,” said Eric Hayashi, president and CEO of LabConnect.
LabConnect has developed a global network of more than 25 regional laboratories to support both routine and highly specialized testing for clinical trials. For this year’s meeting, LabConnect partners gathered in Johnson City, Tenn., to collaborate on best practices, solidify quality initiatives and further their laboratory harmonization strategy. Affiliates from South Korea, Poland, Australia, Israel and the United States attended.
To help achieve harmonization, LabConnect collaborates with the Canadian External Quality Assessment Laboratory (CEQAL) to establish and maintain testing accuracy, data management and analytical support among LabConnect network laboratories in the United States, Europe, Asia-Pacific, Ukraine, South America and India.
“Provision of consistently accurate test results for the duration of a clinical trial — that’s what is needed for proving drug efficacy and safety,” said David W. Seccombe, M.D., Ph.D., FRCPC, founder and managing director of CEQAL. Seccombe, as a key consultant for LabConnect, also attended the annual laboratory meeting.
“By utilizing a meticulously executed program of laboratory harmonization, LabConnect assures clients that global clinical trial data from multiple laboratories on different continents has the same or higher comparability as data produced by a single facility,” Seccombe said.
“This type of collaboration and communication is essential to building a first-class operation to meet the evolving and growing need for sophisticated laboratory and biorepository services,” said Hayashi.
Founded in 2002, LabConnect provides global central laboratory services including routine and specialized laboratory testing, kit building, sample management, data management, biorepository and scientific support services for biopharmaceutical and CRO clients. LabConnect’s unique combination of state-of-the-art technology, world-class laboratories, easy access to emerging markets and extensive specialized testing expertise means the drug development industry can rely on one provider for all of their central laboratory service needs. Learn more at www.labconnectllc.com or connect with LabConnect on LinkedIn.